A Phase 3 interventional study of Risperdal Consta and Placebo in Bipolar Disorder, sponsored by Johnson & Johnson Pharmaceutical Research & Development, L.L.C.. Completed at 52 sites in 10 countries. Open to participants aged 18 Years to 65 Years. Per ClinicalTrials.gov, last updated 2013-07-29.
Sponsored by Johnson & Johnson Pharmaceutical Research & Development, L.L.C. (part of Johnson & Johnson) · Phase 3, Interventional, and Prevention
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 29 studies testing risperidone in Bipolar Disorder — none open to participants now, none under way, none of them phase 3. Risperidone · Bipolar Disorder.
Among the 29 studies testing risperidone in Bipolar Disorder, this one has the largest enrollment, is the only one that started in 2005, is one of 16 in phase 3, and was the 5th registered.
1,686 studies on the registry are indexed under Bipolar Disorder; 268 are open to participants now.
Browse Bipolar Disorder studies →None of the 29 studies testing risperidone in Bipolar Disorder is open now. The open studies under Bipolar Disorder, anywhere →
Risperidone: first FDA approval 1993 (RISPERDAL), first EMA approval 2022. What it is approved for, and how studies give it, is on its page →
Of the 208 Bipolar Disorder studies recruiting now, 59 (28%) set no upper age limit and 136 (65%) stop at 75 or younger; 38 take children under 18; 51 take healthy volunteers.
This study: 18 Years to 65 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
29 studies; the count open now beside each. This study's row is marked.
First in 1997; this study’s year is marked. 1 started in 2005.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 559 is above the median of 64 across 1,281 interventional studies indexed under Bipolar Disorder.
Median enrollment 78 across the 29 interventional studies. Of the 29 that completed or were terminated, 9 (31%) have results posted.
This tab as a report to print or save as PDF → With an account.
14 of 29 have an industry lead sponsor. The 10 most frequent:
This study is registered under Johnson & Johnson Pharmaceutical Research & Development, L.L.C., one of the names counted as Johnson & Johnson. Under that name alone:
Johnson & Johnson Pharmaceutical Research & Development, L.L.C. is the lead sponsor of 465 studies on the registry; none are open to participants now.
39 studies in Bipolar Disorder by Johnson & Johnson: 2 open now, 2 under way, 2 of them phase 3. Of 37 finished, 9 (24%) have results posted.
Among the 39 studies in Bipolar Disorder by Johnson & Johnson, this one is the 3rd largest by enrollment of the 36 interventional ones that give a count, is one of 2 that started in 2005, is one of 28 in phase 3, and was the 7th registered.
Johnson & Johnson’s Bipolar Disorder studies by the year they started, since 1997.
None of the studies under way reaches primary completion within a year.
Among the 29 studies testing risperidone in Bipolar Disorder, from their registry updates:
Nothing recorded among them since 2026-09-25.
Among Johnson & Johnson’s 39 in Bipolar Disorder:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
The purpose of this study is to determine if risperidone is effective and safe in the prevention of mood episodes in patients with bipolar 1 disorder.
RISPERDAL CONSTA (risperidone long-acting injection) may provide substantial improvement, by reducing patient non-compliance, in the long-term treatment of bipolar I disorder. This is a randomized (patients are assigned different treatments based on chance), double-blind, (neither the patient nor the physician knows whether drug or placebo is being taken, or at what dosage) placebo-controlled study to explore the safety and effectiveness of RISPERDAL CONSTA in the prevention of mood episodes in patients with bipolar 1 disorder. This study includes 5 periods: a screening period lasting up to 1 week; an open-label RISPERDAL (oral risperidone) treatment period lasting 3 weeks; an open-label RISPERDAL CONSTA stabilization period lasting 26 weeks; a double-blind period lasting up to 24 months; and an open-label extension with RISPERDAL CONSTA lasting 8 weeks. Efficacy will be assessed using the Young Mania Rating Scale (YMRS), Montgomery-Åsberg Depression Rating Scale (MADRS), Clinical Global Impressions - Severity (CGI-S) scale, Medical Outcomes Study Short Form 36 (SF-36), and the Personal and Social Performance (PSP) scale. Safety will be evaluated throughout the study and includes assessment of adverse events, clinical laboratory tests (including hematology, serum chemistry, blood glucose/lipid profile, prolactin, and urinalysis); electrocardiograms (ECGs), vital signs (pulse and blood pressure), physical examination, body mass index (BMI), and the Extrapyramidal Symptom Rating Scale (ESRS). Oral risperidone (flexible dosage) 1 to 6 mg/day for the first 3 weeks. Risperidone LAI i.m. injections (12.5mg, 25 mg, 37.5 mg, or 50 mg) given every 2 weeks for up to approximately 2.6 years (only 6 months for patients receiving placebo during DB-period)
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Risperdal Consta 12.5 25 37.5 or 50mg intramuscular (IM) injection every 2 weeks
Drug: Risperdal Consta
Placebo Matching placebo intramuscular (IM) injection every 2 weeks
Drug: Placebo
12.5, 25, 37.5 or 50mg intramuscular (IM) injection every 2 weeks
Matching placebo intramuscular (IM) injection every 2 weeks
Number of Participants Who Had a Mood Relapse.
Mood Relapse was defined as: The subject met DSM-IV criteria for a manic, hypomanic, mixed, or depressive episode; or, the subject needed treatment intervention with any mood stabilizer, antipsychotic medication (other than study drug), benzodiazepine (beyond the dosage allowed), or antidepressant medication; or the subject required hospitalization for any bipolar mood episode; or the subject had a YMRS or MADRS score \>12 or a CGI-S score \>4; or a dose increase, or supplementation with oral risperidone or another antipsychotic or mood stabilizer, was needed in the opinion of the investigator.
Time frame: 24 months
Change in Young Mania Rating Scale (YMRS) Scores.
Measure of mania; score range 0 to 60 (lower score = less severity)
Time frame: Baseline and Endpoint (last observation carried forward) of 24 month Double-Blind Period IV
Change in Montgomery-Åsberg Depression Rating Scale (MADRS)
Measure of depression; score range 0 to 60 (lower score = less severity)
Time frame: Baseline and Endpoint (last observation carried forward) of 24 month Double-Blind Period IV
A total of 559 (440 + 119) subjects received at least one dose of study drug. A total of 440 subjects (acute episode or stable on other antipsychotic) entered period II, 382 subjects completed and entered period III. An additional 119 subjects (stable on risperidone) entered period III directly. Overall 501 (382 + 119) subjects entered period III.
| Milestone | RISPERDAL CONSTA | Placebo | Open-Label Oral Risperidone |
|---|---|---|---|
| Started | 0 | 0 | 440 |
| Completed | 0 | 0 | 382 |
| Not completed | 0 | 0 | 58 |
| Withdrew: Death | 0 | 0 | 1 |
| Withdrew: Adverse event | 0 | 0 | 13 |
| Withdrew: Non responder | 0 | 0 | 6 |
| Withdrew: Ineligible to continue trial | 0 | 0 | 7 |
| Withdrew: Lost to follow-up | 0 | 0 | 14 |
| Withdrew: Withdrawal by subject | 0 | 0 | 16 |
| Withdrew: Physician decision | 0 | 0 | 1 |
| Milestone | RISPERDAL CONSTA | Placebo | Open-Label Oral Risperidone |
|---|---|---|---|
| Started | 501 | 0 | 0 |
| Completed | 303 | 0 | 0 |
| Not completed | 198 | 0 | 0 |
| Withdrew: Death | 2 | 0 | 0 |
| Withdrew: Adverse event | 12 | 0 | 0 |
| Withdrew: Non responder | 107 | 0 | 0 |
| Withdrew: Ineligible to continue trial | 5 | 0 | 0 |
| Withdrew: Lost to follow-up | 19 | 0 | 0 |
| Withdrew: Withdrawal by subject | 49 | 0 | 0 |
| Withdrew: Subject non-compliant | 1 | 0 | 0 |
| Withdrew: Physician decision | 1 | 0 | 0 |
| Withdrew: Pregnancy | 2 | 0 | 0 |
| Milestone | RISPERDAL CONSTA | Placebo | Open-Label Oral Risperidone |
|---|---|---|---|
| Started | 154 | 149 | 0 |
| Completed | 117 | 109 | 0 |
| Not completed | 37 | 40 | 0 |
| Withdrew: Adverse event | 1 | 1 | 0 |
| Withdrew: Ineligible to continue the trial | 4 | 4 | 0 |
| Withdrew: Lost to follow-up | 6 | 3 | 0 |
| Withdrew: Withdrawal by subject | 14 | 15 | 0 |
| Withdrew: Physician decision | 10 | 14 | 0 |
| Withdrew: Subject non-compliant | 2 | 1 | 0 |
| Withdrew: Pregnancy | 0 | 2 | 0 |
Mood Relapse was defined as: The subject met DSM-IV criteria for a manic, hypomanic, mixed, or depressive episode; or, the subject needed treatment intervention with any mood stabilizer, antipsychotic medication (other than study drug), benzodiazepine (beyond the dosage allowed), or antidepressant medication; or the subject required hospitalization for any bipolar mood episode; or the subject had a YMRS or MADRS score \>12 or a CGI-S score \>4; or a dose increase, or supplementation with oral risperidone or another antipsychotic or mood stabilizer, was needed in the opinion of the investigator.
| Participants | RISPERDAL CONSTA | Placebo |
|---|---|---|
| Relapsed | 42 (173 to NA) | 76 (82 to NA) |
| Not Relapsed | 98 | 59 |
Measure of mania; score range 0 to 60 (lower score = less severity)
| units on a scale | RISPERDAL CONSTA | Placebo |
|---|---|---|
| Change in Young Mania Rating Scale (YMRS) Scores. | 2.9 ± 7.34 | 9.1 ± 10.78 |
Measure of depression; score range 0 to 60 (lower score = less severity)
| units on a scale | RISPERDAL CONSTA | Placebo |
|---|---|---|
| Change in Montgomery-Åsberg Depression Rating Scale (MADRS) | 2.8 ± 6.66 | 4.9 ± 8.09 |
Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| RISPERDAL CONSTA | — | 13/154 (8.4%) | 28/154 (18.2%) |
| Placebo | — | 25/149 (16.8%) | 24/149 (16.1%) |
| Open-Label Oral Risperidone | — | 8/440 (1.8%) | 81/440 (18.4%) |
| Open Label RISPERDAL CONSTA | — | 38/501 (7.6%) | 155/501 (30.9%) |
| Event | RISPERDAL CONSTA | Placebo | Open-Label Oral Risperidone | Open Label RISPERDAL CONSTA |
|---|---|---|---|---|
| ManiaPsychiatric disorders | 3/154 | 10/149 | 1/440 | 2/501 |
| Bipolar I disorderPsychiatric disorders | 3/154 | 9/149 | 2/440 | 12/501 |
| DepressionPsychiatric disorders | 5/154 | 1/149 | 0/440 | 10/501 |
| Psychotic disorderPsychiatric disorders | 0/154 | 2/149 | 0/440 | 2/501 |
| Bipolar disorderPsychiatric disorders | 0/154 | 1/149 | 1/440 | 2/501 |
| Major depressionPsychiatric disorders | 0/154 | 1/149 | 0/440 | 0/501 |
| Suicide attemptPsychiatric disorders | 0/154 | 1/149 | 1/440 | 1/501 |
| EpilepsyNervous system disorders | 0/154 | 1/149 | 0/440 | 0/501 |
| Diabetes mellitusMetabolism and nutrition disorders | 1/154 | 0/149 | 0/440 | 0/501 |
| Nasal polypsRespiratory, thoracic and mediastinal disorders | 1/154 | 0/149 | 0/440 | 0/501 |
| Event | RISPERDAL CONSTA | Placebo | Open-Label Oral Risperidone | Open Label RISPERDAL CONSTA |
|---|---|---|---|---|
| InsomniaPsychiatric disorders | 12/154 | 9/149 | 23/440 | 66/501 |
| HeadacheNervous system disorders | 11/154 | 10/149 | 33/440 | 28/501 |
| AgitationPsychiatric disorders | 2/154 | 7/149 | 5/440 | 28/501 |
| SommolenceNervous system disorders | 1/154 | 1/149 | 24/440 | 13/501 |
| Weight increasedInvestigations | 7/154 | 1/149 | 3/440 | 27/501 |
| AnxietyPsychiatric disorders | 4/154 | 6/149 | 6/440 | 23/501 |
| Age Continuous(years) | RISPERDAL CONSTA | Placebo | Total |
|---|---|---|---|
| Mean | 39.1 ± 11.81 | 39.2 ± 12.40 | 39.2 ± 12.08 |
| Sex: Female, Male(Participants) | RISPERDAL CONSTA | Placebo | Total |
|---|---|---|---|
| Female | 79 | 68 | 147 |
| Male | 75 | 81 | 156 |
The record gives a start of Feb 2005, a primary completion of Oct 2007 and a completion of Dec 2007. It does not say whether these dates are actual or estimated.
Results were first posted in Feb 2009, 1 year 4 months after primary completion.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Jul 2013. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Risperidone
Johnson & Johnson Pharmaceutical Research & Development, L.L.C. →